U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471516) titled 'Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia' on March 03.
Brief Summary: Background:
Congenital Dyserythropoietic Anemia (CDA) is a group of rare hereditary blood disorders characterized by ineffective erythropoiesis, leading to chronic anemia and organ damage. Current treatment options are very limited, mainly relying on regular blood transfusions, which can cause severe complications over time. Our laboratory research and animal models suggest that Zoledronic acid, a medication commonly used for bone health, may improve ineffective erythropoiesis.
Purpose:
The purpose of this exploratory stud...